Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Source filing unavailable
Q2 2012 · —
Revenue$1.42B$1.42B+17.6% vs Q2 2011 Net Income$386.80M$386.80M+34.3% vs Q2 2011 EPS Diluted$1.61$1.61+36.4% vs Q2 2011 Gross Profit$1,281,800,000+15.7% Operating Income$505,723,000+23.1% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
Free Cash Flowderived$562,685,000+49.8% Margins · derivedGross margin90.2%−1.5 pt vs Q2 2011
Operating margin35.6%+1.6 pt vs Q2 2011
Net margin27.2%+3.4 pt vs Q2 2011